Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock Price Target Raised at The Goldman Sachs Group

Key Points

• Goldman Sachs raised Kiniksa’s price target from $90 to $101 while maintaining a “buy” rating, implying 9.4% potential upside. The average analyst target is $98.43, with eight Buy ratings and one Hold.
• Kiniksa shares rose 3.5% to $92.33, near their 52-week high, following strong quarterly results. Earnings of $0.56 per share and revenue of $285.97 million exceeded analyst expectations.
• The company reported continued commercial momentum for ARCALYST and raised its 2026 revenue outlook to $1.045 billion–$1.050 billion, while its pipeline offers longer-term growth potential.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) had its target price increased by research analysts at The Goldman Sachs Group from $90.00 to $101.00 in a research report issued on Wednesday, Benzinga reports. The firm presently has a "buy" rating on the stock. The Goldman Sachs Group's price objective suggests a potential upside of 9.40% from the stock's current price.

Several other analysts have also issued reports on the company. Wedbush boosted their target price on Kiniksa Pharmaceuticals International from $99.00 to $102.00 and gave the company an "outperform" rating in a research note on Wednesday. Zacks Research downgraded Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 30th. Wall Street Zen downgraded Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "buy" rating in a research note on Sunday, July 12th. Citigroup lifted their price objective on Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the stock a "buy" rating in a report on Wednesday, July 29th. Finally, Wells Fargo & Company boosted their price objective on Kiniksa Pharmaceuticals International from $87.00 to $110.00 and gave the company an "overweight" rating in a research note on Wednesday. Eight research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, Kiniksa Pharmaceuticals International currently has an average rating of "Moderate Buy" and an average target price of $98.43.

Kiniksa Pharmaceuticals International Trading Up 3.5%

Shares of NASDAQ:KNSA traded up $3.12 during mid-day trading on Wednesday, reaching $92.33. The company had a trading volume of 623,253 shares, compared to its average volume of 691,058. The firm has a market cap of $7.20 billion, a price-to-earnings ratio of 94.99 and a beta of 0.04. The company's 50-day moving average price is $78.23 and its 200-day moving average price is $59.23. Kiniksa Pharmaceuticals International has a one year low of $36.56 and a one year high of $92.86.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last posted its quarterly earnings data on Tuesday, October 27th. The company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.37 by $0.19. Kiniksa Pharmaceuticals International had a return on equity of 13.65% and a net margin of 9.59%. The business had revenue of $285.97 million for the quarter, compared to the consensus estimate of $260.66 million. On average, research analysts anticipate that Kiniksa Pharmaceuticals International will post 1.37 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CAO Michael Megna sold 4,600 shares of the firm's stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $80.30, for a total value of $369,380.00. Following the completion of the transaction, the chief accounting officer directly owned 29,062 shares of the company's stock, valued at approximately $2,333,678.60. This trade represents a 13.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 51.98% of the company's stock.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

A number of hedge funds and other institutional investors have recently bought and sold shares of KNSA. Allworth Financial LP lifted its position in shares of Kiniksa Pharmaceuticals International by 42.0% during the second quarter. Allworth Financial LP now owns 453 shares of the company's stock worth $29,000 after acquiring an additional 134 shares in the last quarter. Curry Webb Wealth Management LLC purchased a new position in shares of Kiniksa Pharmaceuticals International in the third quarter valued at $29,000. KBC Group NV bought a new stake in shares of Kiniksa Pharmaceuticals International during the 1st quarter valued at $34,000. Nykredit A S bought a new stake in shares of Kiniksa Pharmaceuticals International during the 2nd quarter valued at $34,000. Finally, USA Financial Formulas bought a new stake in shares of Kiniksa Pharmaceuticals International during the 3rd quarter valued at $69,000. Institutional investors own 53.95% of the company's stock.

More Kiniksa Pharmaceuticals International News

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Positive Sentiment: Analysts raised price targets: Wedbush increased its target from $99 to $102 and maintained an “outperform” rating, while Wells Fargo raised its target from $87 to $110 and upgraded or reaffirmed an “overweight” view. The new targets imply additional upside and reinforce investor confidence in KNSA’s growth outlook. Wedbush analyst recommendation Wells Fargo analyst recommendation
• Positive Sentiment: Quarterly results exceeded expectations: Kiniksa reported third-quarter adjusted earnings of $0.56 per share, versus the $0.32-$0.37 consensus range, and revenue of approximately $286.0 million, above the roughly $260.7 million analyst estimate. Earnings also increased from $0.23 per share a year earlier. Kiniksa third-quarter 2026 results
• Positive Sentiment: Guidance was raised: Kiniksa increased expected 2026 ARCALYST net product revenue to $1.045 billion-$1.050 billion. Third-quarter ARCALYST revenue grew approximately 58% year over year, while penetration among patients with multiple recurrences reached 23%, indicating continued commercial momentum. Kiniksa long-term investor takeaways
• Positive Sentiment: Pipeline progress provides a longer-term catalyst: Pivotal Phase 3 data for KPL-387 is expected in the second half of 2027, offering potential future growth beyond ARCALYST.
• Neutral Sentiment: Reported short interest was listed at zero shares as of October 26, suggesting little measurable short-selling pressure, although the figure may reflect incomplete or unusual reporting data.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company's research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa's principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.